Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Development deals
Research
Spanish gene editor licenses DNA-cutting enzymes for up to $43M
Integra will merge Cas12I nucleases from Caszyme into its gene editing platform FiCAT 2.0.
Darren Incorvaia
Nov 4, 2024 1:46pm
The Column Group biotech taps Surrozen to target lung fibrosis
Nov 4, 2024 11:14am
Boehringer drops obesity drug from Gubra partnership
Oct 31, 2024 1:22pm
Biogen buys in to molecular glues with deal worth up to $1.45B
Oct 30, 2024 10:50am
Neurocrine, Idorsia part ways 2 years after double phase 2 fails
Oct 29, 2024 7:15am
Novartis inks $150M deal for autoimmune molecular glue
Oct 28, 2024 7:00am
